• No results found

Health-related quality of life in patients with psoriatic and rheumatoid arthritis: data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls

N/A
N/A
Protected

Academic year: 2021

Share "Health-related quality of life in patients with psoriatic and rheumatoid arthritis: data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls"

Copied!
4
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Supplementary table S1 Demographics and disease activity measures General

population (n=2323)

RA (n=3898)

PsA

(n=1515) p-value

Age (years), mean (SD) 44.9 (16.5) 55.9 (31.6) 48.1 (12.6) <0.001

Female, n/total (%) 1192/2323

(51.3)

2776/3886 (71.4)

759/1510

(50.3) <0.001 Disease duration (years), median (25th, 75th

percentile) NA 1.9 (0.1, 11.0) 2.0 (0.1, 9.6) 0.97

28 tender joint count, median (25th, 75th percentile)

Baseline NA 6 (3, 11) 4 (2, 8) <0.001

Baseline minus 3 months NA -2 (-6, 0) -1 (-4, 1) <0.001 Baseline minus 6 months NA -3 (-7 ,0) -1 (-4, 0) <0.001 28 swollen joint

count, median (25th, 75th percentile)

Baseline NA 6 (3, 10) 2 (1, 5) <0.001

Baseline minus 3 months NA -2 (-6, 0) -1 (-3, 0) <0.001 Baseline minus 6 months NA -3 (-6, 0) 1 (-3.75, 0) <0.001 Patient’s global

assessment, mean (SD)

Baseline NA 49.7 (24.2) 51.0 (22.6) 0.05

Baseline minus 3 months NA -14.6 (27.1) -14.7 (23.3) 0.89 Baseline minus 6 months NA -14.8 (27.5) -16.6 (26.6) 0.08 Evaluator’s

global assessment, mean (SD)

Baseline NA 39.6 (18.8) 33.5 (16.3) <0.001

Baseline minus 3 months NA -15.8 (20.5) -13.6 (19.1) 0.001 Baseline minus 6 months NA -18.9 (21.8) -16.3 (19.8) <0.001

DAS28, mean (SD)

Baseline NA 4.9 (1.4) 4.2 (1.3) <0.001

Baseline minus 3 months NA -1.1 (1.5) -0.9 (1.2) <0.001 Baseline minus 6 months NA -1.4 (1.5) -1.2 (1.3) <0.001

SDAI, mean (SD)

Baseline NA 25.8 (13.8) 19.2 (10.4) <0.001

Baseline minus 3 months NA -10.1 (13.8) -6.2 (11.4) <0.001 Baseline minus 6 months NA -12.1 (14.6) -8.0 (10.4) <0.001

CDAI, mean (SD)

Baseline NA 23.5 (13.0) 17.6 (9.9) <0.001

Baseline minus 3 months NA -9.2 (12.9) -5.7 (10.6) <0.001 Baseline minus 6 months NA -11.0 (13.6) -7.3 (9.8) <0.001 CDAI, clinical disease activity index; DAS28, 28-joint Disease Activity Score with erythrocyte

sedimentation rate; NA, non-applicable; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SDAI, simplified disease activity index

(2)

Supplementary table S2 Unadjusted means (ANOVA) and estimated marginal means (ANCOVA) adjusted for age and gender of SF-36 component summaries, norm-based scale scores and SF-6D utility scores at 3 and 6 months follow-up

3 months Component

summary/ scale score

Unadjusted analyses, mean (SD)

p-value Estimated marginal means (95%CI)

p-value

RA PsA RA PsA

PCS 34.4 (11.1) 35.1 (10.8) 0.06 36.4 (36.0-36.8) 36.1 (35.5-36.8) 0.55 MCS 48.8 (10.8) 48.9 (11.2) 0.92 48.2 (47.8-48.6) 48.0 (47.4-48.6) 0.60

SF-6D 0.61 (0.10) 0.61 (0.20) 0.42 0.62 (0.61-0.62) 0.61 (0.60-0.62) 0.04

Physical Functioning 32.3 (14.9) 34.9 (14.1) <0.001 33.4 (32.9-34.0) 34.5 (33.7-35.4) 0.03 Role Physical 37.1 (11.2) 38.2 (11.4) 0.003 37.5 (37.1-37.9) 38.1 (37.4-38.7) 0.16 Bodily Pain 39.2 (8.8) 38.8 (8.5) 0.13 39.6 (39.3-39.9) 38.7 (38.2-39.2) 0.003 General Health 39.0 (9.9) 38.5 (10.2) 0.16 39.3 (38.9-39.7) 38.5 (37.9-39.0) 0.02 Vitality 43.3 (10.6) 42.5 (10.4) 0.03 44.0 (43.6-44.4) 42.5 (41.9-43.1) <0.001 Social Functioning 42.9 (11.8) 43.1 (11.8) 0.59 43.4 (43.0-43.9) 43.0 (42.3-43.7) 0.30 Role Emotional 42.8 (13.1) 44.2 (12.9) 0.002 42.9 (42.4-43.4) 43.9 (43.2-44.6) 0.03 Mental Health 46.9 (10.9) 46.9 (10.7) 0.89 47.4 (47.0-47.8) 46.8 (46.2-47.4) 0.15

6 months Component

summary/ scale score

Unadjusted analyses, mean (SD)

p-value Estimated marginal means (95%CI)

p-value

RA PsA RA PsA

PCS 35.5 (11.2) 36.1 (10.8) 0.16 36.3 (35.9-36.8) 35.9 (35.2-36.6) 0.30

MCS 49.6 (10.6) 49.5 (10.7) 0.76 50.1 (49.6-50.5) 49.5 (48.8-50.1) 0.14

SF-6D 0.62 (0.10) 0.62 (0.10) 0.92 0.62 (0.62-0.63) 0.62 (0.61-0.63) 0.33

Physical Functioning 33.9 (15.0) 36.7 (13.6) <0.001 35.1 (34.6-35.7) 36.3 (35.5-37.2) 0.03 Role Physical 38.6 (11.7) 39.7 (11.7) 0.01 39.2 (38.7-39.7) 39.5 (38.8-40.2) 0.50 Bodily Pain 40.1 (9.0) 39.7 (8.7) 0.14 40.6 (40.3-41.0) 39.6 (39.0-40.1) 0.001 General Health 39.6 (10.1) 38.7 (10.2) 0.02 39.9 (39.5-40.3) 38.6 (38.0-39.2) 0.001 Vitality 44.2 (10.8) 43.5 (11.1) 0.06 45.1 (44.7-45.5) 43.5 (42.8-44.1) <0.001 Social Functioning 44.1 (11.5) 44.3 (11.2) 0.68 44.8 (44.4-45.3) 44.2 (43.5-44.9) 0.12 Role Emotional 43.8 (13.0) 45.0 (12.5) 0.007 44.1 (43.6-44.7) 44.8 (44.0-45.6) 0.16 Mental Health 47.8 (10.7) 47.7 (10.5) 0.78 48.4 (48.0-48.9) 47.6 (47.0-48.3) 0.05

PCS, Physical Component Summary; MCS, Mental Component Summary; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SF-6D, short form-6 dimensions utility scores

(3)

Supplementary table S3 Unadjusted means (ANOVA analyses) and estimated marginal means (ANCOVA analyses) adjusted for age and gender (comparisons with the general population) and the respective 28-joint disease activity scores (comparisons between rheumatoid and psoriatic arthritis patients) of SF-36 component summaries, norm-based scale scores and SF-6D utility scores

Baseline

Component summary/ scale score

Unadjusted analyses, mean (SD)

p-value

Estimated marginal means (95%CI)

p-value General

population RA PsA General

population RA PsA

PCS 50.0 (10.1) 29.7 (9.9) 30.5 (9.5) <0.0011,2 0.023

49.7 (49.2-50.1)

30.6 (30.3-30.9)

28.8

(28.3-29.3) <0.0011,2,3 MCS 50.0 (10.2) 46.8 (11.3) 47.1 (11.4) <0.0011,2

0.593

50.0 (49.5-50.5)

47.3 (46.9-47.7)

46.5 (45.9-47.1)

<0.0011,2 0.043 SF-6D 0.80 (0.14) 0.60 (0.12) 0.61 (0.12) <0.0011,2

0.173

0.80 (0.80-0.81)

0.61 (0.61-0.61)

0.59

(0.58-0.59) <0.0011,2,3 Physical Functioning 49.4 (10.8) 27.7 (14.5) 30.5 (13.5) <0.0011,2,3 48.9

(48.3-49.4)

29.2 (28.7-29.6)

27.8 (27.1-28.5)

<0.0011,2 0.0013 Role Physical 49.6 (10.3) 32.9 (9.1) 34.0 (9.9) <0.0011,2

0.0013

49.4 (49.0-49.8)

33.5 (33.2-33.8)

32.9 (32.4-33.4)

<0.0011,2 0.043 Bodily Pain 49.6 (10.3) 33.5 (7.5) 33.6 (7.2) <0.0011,2

0.963

49.4 (49.1-49.8)

34.0 (33.8-34.2)

32.3

(32.0-32.7) <0.0011,2,3 General Health 49.6 (10.3) 37.5 (9.5) 36.8 (9.7) <0.0011,2

0.023

49.5 (49.0-49.9)

38.0 (37.6-38.3)

36.0

(35.5-36.5) <0.0011,2,3 Vitality 49.8 (10.3) 39.6 (10.1) 39.3 (10.3) <0.0011,2

0.693

49.9 (49.5-50.3)

40.7 (40.4-41.0)

38.5

(38.0-39.0) <0.0011,2,3 Social Functioning 49.5 (10.5) 39.1 (12.6) 39.5 (12.3) <0.0011,2

0.593

49.4 (48.9-49.9)

40.1 (39.6-40.5)

38.1

(37.4-38.7) <0.0011,2,3 Role Emotional 49.8 (10.2) 40.2 (13.6) 41.6 (13.6) <0.0011,2

0.0023

49.5 (49.0-50.0)

40.7 (40.2-41.2)

40.4 (39.6-41.1)

<0.0011,2 0.483 Mental Health 49.8 (10.3) 44.3 (11.5) 44.7 (11.1) <0.0011,2

0.633

49.8 (49.4-50.3)

45.1 (44.7-45.5)

43.9 (43.3-44.6)

<0.0011,2 0.0033 3 months

Component summary/ domain

score

Unadjusted analyses, mean (SD)

p-value Estimated marginal means (95%CI)

p-value

RA PsA RA PsA

PCS 34.4 (11.1) 35.1 (10.8) 0.06 35.0 (34.7-35.4) 33.4 (32.8-34.0) <0.001

MCS 48.8 (10.8) 48.9 (11.2) 0.92 49.0 (48.5-49.4) 48.7 (48.0-49.4) 0.48

SF-6D 0.61 (0.10) 0.61 (0.20) 0.42 0.62 (0.61-0.62) 0.60 (0.59-0.61) <0.001 Physical Functioning 32.3 (14.9) 34.9 (14.1) <0.001 33.3 (32.8-33.8)) 32.7 (31.9-33.5) 0.19 Role Physical 37.1 (11.2) 38.2 (11.4) 0.003 37.5 (37.1-37.9) 37.1 (36.5-37.8) 0.35 Bodily Pain 39.2 (8.8) 38.8 (8.5) 0.13 39.6 (39.3-39.9) 37.6 (37.2-38.0) <0.001 General Health 39.0 (9.9) 38.5 (10.2) 0.16 39.3 (38.9-39.7) 37.6 (37.0-38.1) <0.001 Vitality 43.3 (10.6) 42.5 (10.4) 0.03 43.9 (43.5-44.3) 41.8 (41.2-42.4) <0.001 Social Functioning 42.9 (11.8) 43.1 (11.8) 0.59 43.3 (42.9-43.8) 42.2 (41.5-42.9) 0.007

(4)

Role Emotional 42.8 (13.1) 44.2 (12.9) 0.002 43.0 (42.5-43.5) 43.5 (42.7-44.2) 0.31 Mental Health 46.9 (10.9) 46.9 (10.7) 0.89 47.4 (46.9-47.8) 46.4 (45.7-47.0) 0.01

6 months

Component summary/ scale score

Unadjusted analyses, mean (SD)

p-value Estimated marginal means (95%CI)

p-value

RA PsA RA PsA

PCS 35.5 (11.2) 36.1 (10.8) 0.16 36.2 (35.8-36.6) 34.8 (34.2-35.5) <0.001

MCS 49.6 (10.6) 49.5 (10.7) 0.76 50.0 (49.6-50.5) 49.2 (48.5-49.9) 0.05

SF-6D 0.62 (0.10) 0.62 (0.10) 0.92 0.62 (0.62-0.63) 0.61 (0.60-0.62) 0.006

Physical Functioning 33.9 (15.0) 36.7 (13.6) <0.001 34.9 (34.4-35.5) 34.9 (34.1-35.8) 0.99 Role Physical 38.6 (11.7) 39.7 (11.7) 0.01 39.1 (38.7-39.6) 38.7 (38.0-39.4) 0.31 Bodily Pain 40.1 (9.0) 39.7 (8.7) 0.14 40.5 (40.2-40.8) 38.8 (38.3-39.3) <0.001 General Health 39.6 (10.1) 38.7 (10.2) 0.02 39.9 (39.5-40.3) 38.0 (37.3-38.6) <0.001 Vitality 44.2 (10.8) 43.5 (11.1) 0.06 45.1 (44.7-45.5) 42.8 (42.2-43.5) <0.001 Social Functioning 44.1 (11.5) 44.3 (11.2) 0.68 44.7 (44.3-45.2) 43.4 (42.7-44.1) 0.003 Role Emotional 43.8 (13.0) 45.0 (12.5) 0.007 44.0 (43.4-44.5) 44.3 (43.5-45.1) 0.48 Mental Health 47.8 (10.7) 47.7 (10.5) 0.78 48.4 (48.0-48.9) 47.1 (46.4-47.8) 0.002

1General population - RA; 2General population - PsA; 3RA - PsA. MCS, mental component summary;

PCS, physical component summary; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SF-6D, short form-6 dimensions utility scores

Referenties

GERELATEERDE DOCUMENTEN

Presence of another disease, genetic make up, age, and environment can correlate with the treatment outcome.. ACPA = anticitrullinated protein antibodies; ACR = American College

P-values resulted from two-sided Chi-square test between patients and controls, wild type allele versus variant-type allele... Different genotypes

Lines represent number of cases required to detect differences with sig- nificance level of 1.10 –4 (10K array are lines at lower level) and 1.10 –6 (Genome-wide P-value are lines

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden. Downloaded

Drug target TNF gene and promoter region, TNF receptor gene Drug target immunoglobulin G fragment C receptor type IIa, type IIIa and b Biological milieu genes such as genes in the

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden. Downloaded

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden. Downloaded

Dank aan veel mensen buiten mijn werk die tijdens deze onderzoekspe- riode een belangrijke motivatie voor mij waren om niet ‘in Leiden te zijn’ of aan onderzoek te denken. Zonder